Analyst Research Report Snapshot

Title:

BIOINVENT INTERNATIONAL - FOCUSED ONTO CANCER

Price:

$10.00

Provider:

Edison Investment Research

Date:

14 Mar 2013

Pages:

4

Type:

AcrobatPDF

Companies referenced:

BINV.ST

Available for Immediate Download
Summary:

FY12 results showed revenues and grants of SEK55.5m with costs of SEK246.6m, including SEK49.2m of provisions and restructuring costs. The company has restructured to give a stated cost base of SEK75m before revenues in 2013. There was SEK100m of cash on 31 December. The BI-505 Phase I dose-escalating and safety study in relapsed and refractory multiple myeloma (MM) indicated a dose of 10mg/kg. BI-505 will progress to a small Phase IIa during 2013. BioInvent intends to partner BI-505 in 2014. Two preclinical antibodies have entered development.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.